Chicago – Advanced Cooling Therapy (ACT), has received a license for commercial sale of its first product, the Esophageal Cooling Device (ECD), from Health Canada. The product, which is used to control patient temperature, is now available to medical professionals in Canada.
The ECD is a single use, fully enclosed triple lumen system that is inserted into the esophagus to modulate and control patient temperature when clinically indicated. Two lumens attach to existing temperature modulation equipment while a third lumen simultaneously allows gastric decompression and drainage. The ECD can be rapidly inserted by most trained health care professionals, in similar fashion to a standard gastric tube, and can be used to control patient temperature in the operating room, recovery room, emergency room, or ICU. No other product on the market is approved to use the esophageal environment for whole-body temperature modulation.
ACT’s President and Co-Founder, Erik Kulstad, MD, MS, said, "Monitoring and controlling a patient's temperature is an increasingly important component of patient care for a growing number of clinical conditions. As an Emergency Room physician, I often face the challenges associated with traditional temperature management – bulky blankets, expensive machines, and invasive catheter procedures. The ECD is safe, easy to use, and cost-effective, and we look forward to commercialization in Canada."
Health Canada is the Federal department in Canada that reviews medical devices to assess their safety and effectiveness before being authorized for sale. The ECD received CE marking for European sale in April, 2014 and is pending regulatory clearance in the US.
Advanced Cooling Therapy’s novel technology platform provides improved methods to control patient temperature where clinically indicated using the esophageal environment.
Source: Advanced Cooling Therapy